Icosavax Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
August 02, 2021 16:01 ET | Icosavax, Inc.
SEATTLE, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
CureVac Logo mit Claim RGB.jpg
CureVac Announces U.S. Patent Grant for mRNA Vaccination of Infants Against RSV
January 08, 2019 07:00 ET | CureVac AG
Important New Patent to Allow CureVac to Develop Vaccine Candidate for Neglected Respiratory Condition TÜBINGEN, Germany and BOSTON, Jan. 08, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully...
Infectious Diseases
Infectious Diseases a Hot Topic at the International Society for Heart and Lung Transplantation 38th Annual Meeting and Scientific Sessions NICE, FR, April 13, 2018 (GLOBE NEWSWIRE) -- During Oral Session 38 at the International Society for Heart and Lung Transplantation (ISHLT) 38th Annual Meeting & Scientific Sessions, two studies...